ID: ALA4592496

Max Phase: Preclinical

Molecular Formula: C9H12ClF2N2O14P3

Molecular Weight: 538.57

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  O=c1ccn([C@@H]2O[C@](F)(COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@]2(F)Cl)c(=O)[nH]1

Standard InChI:  InChI=1S/C9H12ClF2N2O14P3/c10-9(12)5(16)8(11,26-6(9)14-2-1-4(15)13-7(14)17)3-25-30(21,22)28-31(23,24)27-29(18,19)20/h1-2,5-6,16H,3H2,(H,21,22)(H,23,24)(H,13,15,17)(H2,18,19,20)/t5-,6-,8-,9-/m1/s1

Standard InChI Key:  JSZRWPLFOYFPBV-SQEXRHODSA-N

Associated Targets(Human)

DNA polymerase alpha subunit 225 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

DNA polymerase beta 23632 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

DNA polymerase gamma subunit 1 50 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Hepatitis C virus NS5B RNA-dependent RNA polymerase 3026 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 538.57Molecular Weight (Monoisotopic): 537.9158AlogP: -0.66#Rotatable Bonds: 8
Polar Surface Area: 244.14Molecular Species: ACIDHBA: 11HBD: 6
#RO5 Violations: 3HBA (Lipinski): 16HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 0.89CX Basic pKa: CX LogP: -1.05CX LogD: -8.46
Aromatic Rings: 1Heavy Atoms: 31QED Weighted: 0.18Np Likeness Score: 0.80

References

1. Wang G, Dyatkina N, Prhavc M, Williams C, Serebryany V, Hu Y, Huang Y, Wan J, Wu X, Deval J, Fung A, Jin Z, Tan H, Shaw K, Kang H, Zhang Q, Tam Y, Stoycheva A, Jekle A, Smith DB, Beigelman L..  (2019)  Synthesis and Anti-HCV Activities of 4'-Fluoro-2'-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4'-Fluoro-2'- C-methyluridine 5'-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection.,  62  (9): [PMID:30951311] [10.1021/acs.jmedchem.9b00143]

Source